Kangfang Biologics (09926.HK) saw its intraday decline widen to 6%, closing at HK$94.75. The company recently announced its interim results for the six months ended June 30, reporting a loss attributable to shareholders of HK$424 million, compared to a loss of HK$570 million in the same period last year, with a loss per share of 46 cents. No dividend was declared.
